Gain Therapeutics, Inc. GANX 深 滬
已收盤 07-18 16:00:00 美东时间
1.585
-0.025
-1.55%
華盛通- 最 高1.64
- 今 開1.61
- 成交量 20.99万股
- 最 低 1.565
- 昨 收 1.61
- 總市值 4746.38万
- 52周最高 3.19
- 市盈率 靜 --
- 換手率 0.70%
- 52周最低 0.89
- 委 比 90.72%
- 總股本 2994.56万
- 歷史最高 17.93
- 量 比 0.48
- 振 幅 4.66%
- 歷史最低 0.89
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus
U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were mixed.
07-16 18:08
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Shares of Data Storage Corporation (NASDAQ:DTST) rose sharply in pre-market tra...
07-16 18:04
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
Gain Therapeutics announced the pricing of a public offering of 4.5 million shares of common stock and warrants to purchase 2.25 million shares, priced at $3.11 per set of securities. The company expects to raise approximately $7 million, excluding underwriting discounts. The offering is set to close on July 17 and the proceeds will be used for clinical development of its lead candidate GT-02287 for neurodegenerative diseases like GBA1 Parkinson’...
07-16 13:03
Gain Therapeutics announces proposed public offering
Gain Therapeutics (NASDAQ:GANX) announced on Tuesday that it is proposing to offer and sell shares of its common stock and warrants to purchase common stock in an underwritten public offering. The com...
07-16 04:41
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
Gain Therapeutics reported that its Phase 1b clinical trial for GT-02287 in Parkinson’s Disease patients reached the enrollment goal of 16 participants ahead of schedule by June 30, 2025. Biomarker analysis from cerebrospinal fluid samples, initially expected in 1Q 2026, will now be available earlier in 4Q 2025. The company extended the patient screening window to July 31, 2025, and plans to request a dosing extension beyond the 90-day protocol. ...
06-30 20:05
Gain Therapeutics Doubles Authorized Common Stock Shares
Gain Therapeutics ( ($GANX) ) has shared an update. On June 24, 2025, Gain Ther...
06-25 05:29
Gain Therapeutics to Participate in Upcoming Investor Conferences
Gain Therapeutics的CEO Gene Mack将参加H.C. Wainwright神经科学会议和BIO 2025大会。具体安排：6月17日7:00 a.m. EST参与虚拟讨论，6月18日1:45 p.m. EST在波士顿会议中心153C室做公司介绍。Gain Therapeutics专注于开发下一代变构小分子疗法，其主要药物GT-02287正在评估治疗帕金森病及其他相关疾病。会议注册者可通过联系代表或BIO平台安排一对一会议，未参会者可通过ir@gaintherapeutics.com联系管理层。
06-10 12:00
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
<p>Gain Therapeutics, Inc. announced an oral presentation at the GBA1 Meeting 2025 in Montreal, Canada, set for June 5-7. The presentation, scheduled for June 5 at 11:20 p.m. EST, will be delivered by Jonas Hannestad, M.D., Ph.D., the Company's Chief Medical Officer. Gain is focused on developing next-generation allosteric therapies, with its lead candidate, GT-02287, currently in a Phase 1b trial for Parkinson’s disease, and showing potential fo...
05-29 12:45
Gain Therapeutics announces $100M mixed shelf offering
Gain Therapeutics (NASDAQ:GANX) has filed a shelf registration to offer up to $100M in various securities. The potential offerings may include common stock, preferred stock, warrants, debt securities,...
05-29 05:16
